1141-37-3

Usage

InChI:InChI=1/C11H13Cl2NO2/c12-5-7-14(8-6-13)10-3-1-9(2-4-10)11(15)16/h1-4H,5-8H2,(H,15,16)

Upstream product

• 6259-79-6 4-[bis-(2-chloro-ethyl)-amino]-benzoic acid ethyl ester 
• 1208-03-3 4-(bis(2-chloroethyl)amino)benzaldehyde 
• 3086-06-4 4-benzoyl-L-glutamic acid 
• 15716-30-0 ethyl 4-benzoate 
• 120-07-0 2,2'-(phenylimino)bis[ethanol] 
• 553-27-5 aniline mustard 
• 91645-48-6 methyl 4-benzoate 
• 62-23-7 4-nitro-benzoic acid 
• 99-77-4 ethyl 4-nitrobenzoate 
• 150-13-0 4-amino-benzoic acid 
• 18144-47-3 tert-butyl 4-aminobenzoate 
• 94-09-7 p-aminoethylbenzoate 
• 123724-54-9 di-tert-butyl 4-benzoyl-L-glutamate 
• 123724-57-2 di-tert-butyl 4-benzoyl-L-glutamate 

Downstream Products

• 1027011-76-2 C₁₈H₁₄Cl₅NO₃ 
• 136484-00-9 Cab-Gln-Trp-Ala-Val-Gly-His(Dnp)-LeuΨ(CH2NH)Met-NH2 
• 15944-88-4 4-[N,N-bis(2-chloroethyl)amino]benzoyl chloride 
• 191214-22-9 (3-{[4-({4-[(4-{4-[Bis-(2-chloro-ethyl)-amino]-benzoylamino}-1-methyl-1H-pyrrole-2-carbonyl)-amino]-1-methyl-1H-pyrrole-2-carbonyl}-amino)-1-methyl-1H-pyrrole-2-carbonyl]-amino}-propyl)-carbamic acid tert-butyl ester 
• 197705-46-7 (2-{[4-({4-[(4-{4-[Bis-(2-chloro-ethyl)-amino]-benzoylamino}-1-methyl-1H-pyrrole-2-carbonyl)-amino]-1-methyl-1H-pyrrole-2-carbonyl}-amino)-1-methyl-1H-pyrrole-2-carbonyl]-amino}-ethyl)-carbamic acid tert-butyl ester 
• 197705-47-8 (4-{[4-({4-[(4-{4-[Bis-(2-chloro-ethyl)-amino]-benzoylamino}-1-methyl-1H-pyrrole-2-carbonyl)-amino]-1-methyl-1H-pyrrole-2-carbonyl}-amino)-1-methyl-1H-pyrrole-2-carbonyl]-amino}-butyl)-carbamic acid tert-butyl ester 
• 197705-54-7 (4-{[4-({4-[(4-{4-[Bis-(2-chloro-ethyl)-amino]-benzoylamino}-1-methyl-1H-pyrrole-2-carbonyl)-amino]-1-methyl-1H-pyrrole-2-carbonyl}-amino)-1-methyl-1H-pyrrole-2-carbonyl]-amino}-phenyl)-carbamic acid tert-butyl ester 
• 197705-50-3 3-[(N-butoxycarbonyl)-N-(2-butoxycarboxamidoethyl)aminopropyl]-1-methyl-4-(1-methyl-4-{1-methyl-4-[p-N,N-bis-(2-chloroethyl)aminobenzamido]pyrrole-2-carboxamido}pyrrole-2-carboxamido)pyrrole-2-carboxamide 

Relevant academic research and scientific papers

Discovery of N-(2-Amino-4-Fluorophenyl)-4-[bis-(2-Chloroethyl)-Amino]-Benzamide as a Potent HDAC3 Inhibitor

In discovery of HDAC inhibitors with improved activity and selectivity, fluorine substitution was performed on our previously derived lead compound. The synthesized molecules N-(2-amino-4-fluorophenyl)-4-[bis-(2-chloroethyl)-amino]-benzamide (FNA) exhibited class I (HDAC1, 2, and 3) selectivity in the in vitro enzymatic assay and especially potent against HDAC3 activity (IC50: 95.48 nM). The results of in vitro antiproliferative assay indicated that FNA exhibited solid tumor cell inhibitory activities with IC50 value of 1.30 μM against HepG2 cells compared with SAHA (17.25 μM). Moreover, the in vivo xenograft model study revealed that FNA could inhibit tumor growth with tumor growth inhibition (TGI) of 48.89% compared with SAHA (TGI of 48.13%). Further HepG2 cell–based apoptosis and cell cycle studies showed that promotion of apoptosis and G2/M phase arrest make contributions to the antitumor activity of FNA. In addition, drug combination results showed that 0.5 μM of FNA could improve the anticancer activity of taxol and camptothecin. The present studies revealed the potential of FNA utilized as a high potent lead compound for further discovery of isoform selective HDAC inhibitors.

Synthesis, characterization, and antitumor activity of rare earth metal complexes of benzoic acid nitrogen mustard

Benzoic acid nitrogen mustard and its rare earth metal complexes were synthesized and characterized by elemental analyses, IR, electronic spectrum, and EPR. The interaction of synthesized complexes with Ct-DNA was investigated and reviewed as a mixed manner of both intercalation and alkylation via fluorescence titration. Their biological activities were also evaluated in K562 and Vero cell lines, indicating that complexes had a significant inhibitory effect; however, there was no synergistic effect instead of antagonistic effect compared to benzoic acid nitrogen mustard. The possible mechanism through cellular apoptosis was also explored by comet assay.

Design and synthesis of novel nitrogen mustard-evodiamine hybrids with selective antiproliferative activity

A series of novel nitrogen mustard-evodiamine hybrids were synthesized and evaluated for their antitproliferative properties. The antiproliferative activities of 10a–d, 11a–d, and 12a–d against four different kinds of human cancer cell lines (PC-3, HepG2, THP-1 and HL-60) and human normal peripheral blood mononuclear cells (PBMC) were determined. The results showed that all the target hybrid compounds exhibited antiproliferative activities against tested human tumor cell lines to some extent and no antiproliferative activities (>200 μM) against human normal PBMC cells. The antiproliferative selectivity between tumorous and normal cells was very useful for further antitumor drug development. Among the target compounds, 12c showed the strongest cytotoxicity against two tumor cell lines (THP-1 and HL-60) with IC50 values of 4.05 μM and 0.50 μM, respectively, and selected for further mechanism study in HL-60 cells. The results showed that 12c could induce HL-60 cells apoptosis and arrest at G2 phase at low sub-micromolar concentrations via mitochondria-related pathways.

Novel hybrids of brefeldin A and nitrogen mustards with improved antiproliferative selectivity: Design, synthesis and antitumor biological evaluation

A series of novel conjugates of brefeldin A (11a?c, 12a?c and 13a?c) were obtained by introducing a variety of nitrogen mustards at 4-OH or 7-OH position to explore more efficacious and less toxic antitumor agents. The antiproliferative activities were te

Design and synthesis of chromone-nitrogen mustard derivatives and evaluation of anti-breast cancer activity

Chromone has emerged as one of the most important synthetic scaffolds for antitumor activity, which promotes the development of candidate drugs with better activity. In this study, a series of nitrogen mustard derivatives of chromone were designed and syn

Novel diosgenin–amino acid–benzoic acid mustard trihybrids exert antitumor effects via cell cycle arrest and apoptosis

In discovering new powerful antitumor agents, two series of novel diosgenin–amino acid–benzoic acid mustard trihybrids (7a–7 g and 12a–12 g) were designed and synthesized. The antiproliferative activities were tested against five human tumor cell lines an

Design and synthesis of β-carboline derivatives with nitrogen mustard moieties against breast cancer

To discover the promising antitumor agents, a series of β-carboline derivatives with nitrogen mustard moieties were designed and synthesized. Most target derivatives showed antiproliferative activity against MCF-7 and MDA-MB-231 cells. Among them, (1-meth

A class β . Preparation method and anti-tumor application

The invention discloses β -carbofuran mustard derivatives as well as a preparation method and application thereof, and belongs to the field of natural medicines and medicinal chemistry. The invention specifically relates to a preparation method of a serie

PARP Inhibitor - alkylated bifunctional molecule and preparation method and application thereof

The invention discloses a potent polyadenine diphosphate ribose polymerase inhibitor (Poly ADP-Ribose Polymerase). PARP) The inhibitors - are alkylated bifunctional molecules and the present invention relates to compounds having the structure of Formula I, and also to pharmaceutically acceptable salts and solvates thereof. The preparation method comprises the following steps: condensation of 5 - [(3,4 -dihydro -4 - oxo -1 - phthalazinyl) methyl] -2 -fluorobenzoic acid and N-Boc - piperazine condensation and after-deprotection Boc groups and finally performing condensation connection with a mustard group to obtain the compound shown I. The invention further relates to a pharmaceutical composition containing the compound of the formula I and a pharmaceutical use thereof, and can be used for treating tumors and other targets PARP or DNA. .

Benzoic acid nitrogen mustard fragment-containing compound and preparation method and use thereof

The invention relates to the field of natural medicine and medicine chemistry, and particularly relates to a compound containing benzoic acid nitrogen mustard fragment and a preparation process and use, in particular to a compound which introduces a benzoic acid nitrogen mustard fragment at a 4'-OH through a linking group after derivatization of the 6, 7-position of scutellarin, and a pharmaceutically acceptable salt thereof. The method also relates to the preparation process and antitumor activity of these compounds. The method of the benzoic acid nitrogen mustard fragment-containing compoundis shown in the general formula I, wherein m, n are as described in the claims and the specification. The formula is shown in the description.